import { WomensHealthContent } from '../types';

export const premenstrualDisorders: LegacyWomensHealthContent = {
  id: 'condition-premenstrual-disorders',
  type: 'condition',
  name: 'Premenstrual Disorders',
  alternateNames: ['PMS', 'PMDD', 'Premenstrual syndrome', 'Premenstrual dysphoric disorder'],

  levels: {
    1: {
      level: 1,
      summary: 'Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) cause physical and emotional symptoms in the week or two before your period that improve once your period starts.',
      explanation: `**What is PMS?**
PMS is a group of symptoms that many women experience before their period. They usually go away within a few days of your period starting.

**Common PMS Symptoms:**
- Bloating
- Breast tenderness
- Headaches
- Mood swings
- Irritability
- Fatigue
- Food cravings
- Trouble sleeping

**What is PMDD?**
PMDD is a more severe form of PMS that significantly affects daily life. It includes more intense emotional symptoms.

**PMDD Symptoms:**
- Severe mood swings
- Depression or hopelessness
- Intense anger or irritability
- Anxiety or tension
- Difficulty concentrating
- Feeling out of control

**Key Feature:**
- Symptoms happen in the 1-2 weeks BEFORE your period
- They go away within a few days of your period starting
- There should be a symptom-free time during your cycle

**Treatment Options:**
- Lifestyle changes (exercise, diet, sleep)
- Over-the-counter pain relievers
- Birth control pills (for some women)
- Antidepressants (for PMDD)`,
      keyTerms: [
        { term: 'PMS', definition: 'Premenstrual syndrome - physical and emotional symptoms before your period' },
        { term: 'PMDD', definition: 'Premenstrual dysphoric disorder - a severe form of PMS affecting mood' },
        { term: 'luteal phase', definition: 'The second half of your menstrual cycle, after ovulation' },
      ],
      analogies: ['Think of PMS like a wave that comes before your period - it builds up, peaks, then recedes when your period arrives.'],
      examples: ['Feeling unusually tearful and having chocolate cravings the week before your period', 'Having conflicts at work that only seem to happen before your period'],
    },
    2: {
      level: 2,
      summary: 'Premenstrual syndrome encompasses physical and psychological symptoms in the luteal phase, while PMDD is a severe form with predominant mood symptoms that meets specific DSM-5 criteria and significantly impairs functioning.',
      explanation: `**PMS Criteria:**
- At least one affective and one somatic symptom
- Luteal phase (last 2 weeks of cycle)
- Relief within a few days of menses
- Affects work, relationships, or activities
- Confirmed by 2 cycles of prospective charting

*Affective Symptoms:*
- Irritability
- Depression
- Anxiety
- Mood lability
- Confusion

*Somatic Symptoms:*
- Bloating
- Breast tenderness
- Headache
- Swelling
- Weight gain

**PMDD Diagnostic Criteria (DSM-5):**

*Required:*
- 5+ symptoms present in final week before menses
- Symptoms improve within a few days of menses onset
- Minimal or absent in week after menses
- At least one mood symptom

*Core Symptoms (â‰¥1 required):*
1. Marked affective lability
2. Marked irritability or anger
3. Markedly depressed mood
4. Marked anxiety or tension

*Additional Symptoms:*
- Decreased interest in usual activities
- Difficulty concentrating
- Lethargy
- Appetite changes
- Sleep disturbance
- Feeling overwhelmed
- Physical symptoms

**Prevalence:**
- PMS: 30-40% of women
- PMDD: 3-8% of women
- Symptoms typically begin in mid-20s

**Prospective Symptom Tracking:**
- Required for diagnosis
- Daily rating scale for 2 cycles
- Distinguishes from other mood disorders
- Confirms luteal phase pattern`,
      keyTerms: [
        { term: 'prospective charting', definition: 'Daily symptom tracking over 2+ cycles to confirm timing pattern' },
        { term: 'affective lability', definition: 'Rapid mood changes, tearfulness, or sensitivity to rejection' },
        { term: 'somatic symptoms', definition: 'Physical symptoms like bloating, breast tenderness, headache' },
        { term: 'luteal phase', definition: 'The 14-day period between ovulation and menstruation' },
      ],
    },
    3: {
      level: 3,
      summary: 'Premenstrual disorders result from abnormal sensitivity to normal hormonal fluctuations, with management including lifestyle modifications, SSRIs (which can be used continuously or luteal-phase only), and hormonal therapies to eliminate ovulation.',
      explanation: `**Pathophysiology:**

*Not Hormone Abnormality:*
- Hormone levels are normal
- Abnormal CNS sensitivity to normal fluctuations
- Particularly to progesterone and its metabolite allopregnanolone

*Serotonin Hypothesis:*
- Reduced serotonergic activity in luteal phase
- SSRIs effective even with intermittent dosing
- Rapid response (within 1-2 days)

*Neuroactive Steroids:*
- Allopregnanolone is GABA modulator
- Fluctuations affect mood-regulating circuits

**Evaluation:**

*Prospective Symptom Tracking:*
- Daily Record of Severity of Problems (DRSP)
- At least 2 cycles
- 30% increase in symptoms in luteal phase
- Confirms timing pattern

*Exclude Other Conditions:*
- Major depressive disorder
- Anxiety disorders
- Thyroid disease
- Perimenopause
- Medical conditions exacerbated by menses

**Treatment - Stepwise Approach:**

*Level 1 - Lifestyle:*
- Regular exercise (aerobic)
- Dietary modifications (complex carbs, limit salt, caffeine, alcohol)
- Sleep hygiene
- Stress management
- Calcium 1000-1200 mg/day

*Level 2 - Supplements:*
- Calcium (evidence-based)
- Vitamin B6 (up to 100 mg/day)
- Chasteberry (Vitex)
- Limited evidence for evening primrose, magnesium

*Level 3 - Pharmacotherapy:*
- SSRIs (first-line for PMDD)
- Continuous or luteal-phase dosing
- Response within 1-2 cycles

*Level 4 - Hormonal:*
- Combined oral contraceptives (24/4 regimen)
- GnRH agonists (with add-back for long-term)`,
      keyTerms: [
        { term: 'DRSP', definition: 'Daily Record of Severity of Problems; validated PMDD symptom tracking tool' },
        { term: 'luteal-phase dosing', definition: 'Taking medication only during the 2 weeks before menses' },
        { term: 'allopregnanolone', definition: 'Progesterone metabolite that modulates GABA receptors' },
        { term: 'Vitex', definition: 'Chasteberry; herbal supplement with some evidence for PMS' },
      ],
      clinicalNotes: 'SSRIs work quickly in PMDD (1-2 days) unlike in major depression (2-4 weeks), supporting a different mechanism. Yaz (drospirenone/EE) is FDA-approved for PMDD. Luteal-phase SSRI dosing is effective and reduces side effect burden.',
    },
    4: {
      level: 4,
      summary: 'Advanced PMDD management addresses treatment-resistant cases, perimenopause-related symptom changes, comorbidities, and the role of surgical menopause for severe refractory cases.',
      explanation: `**SSRI Details:**

*Evidence-Based Options:*
- Fluoxetine 20 mg
- Sertraline 50-150 mg
- Paroxetine 10-30 mg
- Escitalopram 10-20 mg

*Dosing Strategies:*
- Continuous: Throughout cycle
- Luteal: Start at ovulation or symptom onset
- Symptom-onset: Only when symptoms begin

*Treatment Failure:*
- Try different SSRI
- Increase dose
- Switch to continuous dosing
- Add hormonal therapy

**Hormonal Therapies:**

*Oral Contraceptives:*
- Yaz (drospirenone/EE 20 mcg): FDA-approved for PMDD
- 24/4 regimen better than 21/7
- Extended or continuous cycling may help
- Not effective for all women

*GnRH Agonists:*
- Medical oophorectomy
- Very effective but significant side effects
- Requires add-back therapy (estrogen + progestin)
- Reserved for severe, refractory cases

*Surgical Oophorectomy:*
- Definitive treatment
- Only for severe refractory PMDD
- Requires trial of GnRH agonist first
- Long-term HRT needed if premenopausal

**Comorbidities:**

*Major Depression:*
- May coexist with PMDD
- PMDD symptoms worsen other mood disorders
- Continuous SSRI may be needed
- May need higher doses

*Anxiety Disorders:*
- Common comorbidity
- Cognitive behavioral therapy helpful
- Treat both conditions

**Perimenopause:**
- PMDD symptoms often worsen
- Irregular cycles complicate treatment
- Consider continuous hormonal therapy
- May improve after menopause

**Emerging Treatments:**

*Neurosteroid Modulators:*
- Sepranolone (PMDD-specific development)
- Blocks allopregnanolone effects
- Phase 2/3 trials

*Esketamine:*
- Rapid antidepressant
- Potential for acute symptom relief
- Research ongoing`,
      keyTerms: [
        { term: 'symptom-onset dosing', definition: 'Starting SSRI only when symptoms begin, typically 3-5 days before menses' },
        { term: 'add-back therapy', definition: 'Hormone replacement given with GnRH agonists to prevent menopausal symptoms' },
        { term: 'sepranolone', definition: 'Investigational neurosteroid modulator specifically targeting PMDD' },
        { term: 'medical oophorectomy', definition: 'Using medication (GnRH agonist) to suppress ovarian function' },
      ],
      clinicalNotes: 'Before considering surgical oophorectomy, confirm response to GnRH agonist trial. Bilateral oophorectomy in young women requires lifelong hormone therapy and has long-term health implications. Perimenopause worsens PMDD for many women.',
    },
    5: {
      level: 5,
      summary: 'Expert PMDD care involves understanding the neurobiology of hormonal sensitivity, addressing diagnostic challenges, implementing multidisciplinary approaches, and advocating for recognition of PMDD as a legitimate medical condition.',
      explanation: `**Neurobiology Advances:**

*Allopregnanolone Sensitivity:*
- Normal hormone levels, abnormal response
- GABA-A receptor modulation
- Rapid mood regulation effects
- Target for novel therapies

*Genetic Factors:*
- ESC/E(Z) gene complex
- Affects hormone-sensitive gene expression
- May explain individual vulnerability

*Inflammatory Markers:*
- Elevated inflammatory cytokines
- May contribute to symptoms
- Research target

**Diagnostic Challenges:**

*Overlapping Conditions:*
- Premenstrual exacerbation of underlying disorder
- Major depression with premenstrual worsening
- Bipolar disorder
- Borderline personality disorder

*Key Differentiators:*
- Symptom-free interval (follicular phase) in PMDD
- Prospective charting essential
- May have comorbid conditions treated differently

**Validation and Advocacy:**

*Historical Dismissal:*
- "It's just PMS"
- Symptoms minimized
- Lack of research funding
- Gender bias in medicine

*Current Recognition:*
- DSM-5 diagnosis
- FDA-approved treatments
- Growing research base
- Patient advocacy organizations

**Multidisciplinary Care:**

*Team Approach:*
- Gynecology
- Psychiatry
- Primary care
- Psychology
- Nutrition

*Patient Education:*
- Validate experience
- Explain neurobiology
- Discuss treatment options
- Set realistic expectations

**Quality of Life Impact:**

*Documented Effects:*
- Relationship disruption
- Work productivity loss
- Suicidal ideation (20% of severe PMDD)
- Quality of life comparable to major depression

*Addressing Impact:*
- Workplace accommodations
- Relationship counseling
- Safety planning if needed
- Support groups

**Research Priorities:**
- Biomarkers for diagnosis
- Predictors of treatment response
- Novel therapeutic targets
- Prevention strategies

**Patient-Centered Communication:**

*Key Messages:*
- "This is a real medical condition"
- "It's treatable"
- "Your symptoms are valid"
- "We will work together to find what helps"

*Shared Decision-Making:*
- Lifestyle vs. medication
- Continuous vs. intermittent dosing
- Hormonal approaches
- Fertility considerations`,
      keyTerms: [
        { term: 'premenstrual exacerbation', definition: 'Worsening of an underlying disorder premenstrually, distinct from PMDD' },
        { term: 'ESC/E(Z) complex', definition: 'Gene complex affecting hormone sensitivity, implicated in PMDD' },
        { term: 'symptom-free interval', definition: 'Period during follicular phase with minimal or no symptoms; key diagnostic feature' },
        { term: 'gender bias', definition: 'Historical tendency to dismiss or minimize women\'s health conditions' },
      ],
      clinicalNotes: 'PMDD is associated with suicidal ideation in 20% of patients - assess safety. Validation of symptoms is therapeutic. The distinction between PMDD and premenstrual exacerbation of another disorder affects treatment approach.',
    },
  },

  media: [],
  citations: [
    {
      id: 'acog-premenstrual-pb',
      type: 'article',
      title: 'ACOG Practice Bulletin: Premenstrual Syndrome',
      source: 'American College of Obstetricians and Gynecologists',
      license: 'Copyright ACOG',
    },
    {
      id: 'dsm-5-pmdd',
      type: 'textbook',
      title: 'DSM-5: Premenstrual Dysphoric Disorder',
      source: 'American Psychiatric Association',
      license: 'Copyright APA',
    },
  ],
  crossReferences: [
    { targetId: 'concept-menstrual-cycle-explained', targetType: 'concept', relationship: 'related', label: 'Menstrual Cycle' },
    { targetId: 'concept-postpartum-depression', targetType: 'concept', relationship: 'related', label: 'Postpartum Depression' },
    { targetId: 'concept-perimenopause-mood-changes', targetType: 'concept', relationship: 'related', label: 'Perimenopause Mood' },
  ],
  tags: {
    systems: ['nervous', 'reproductive'],
    topics: ['womens-health', 'patient-education', 'mental-health', 'gynecology'],
    keywords: ['PMS', 'PMDD', 'premenstrual syndrome', 'mood symptoms', 'luteal phase'],
    clinicalRelevance: 'high',
    examRelevance: { usmle: true, shelf: ['obgyn', 'psychiatry'] },
  },
  createdAt: '2026-01-24T00:00:00.000Z',
  updatedAt: '2026-01-24T00:00:00.000Z',
  version: 1,
  status: 'published',
};
